(3S,4R)-4-(3,4-Dimethoxyphenyl)Pyrrolidine-3-Carboxylic Acid

Atomoxetine Analogue Assembly Exploiting the (3S,4R) Configuration in Pyrrolidine Carboxylate Backbone

In the synthesis of norepinephrine reuptake inhibitors structurally related to atomoxetine, the carboxyl group is first activated with 1.05 eq of 1,1′-carbonyldiimidazole in anhydrous tetrahydrofuran at −5 °C to 0 °C under a nitrogen blanket. After 45 min of activation monitored by inline ReactIR to ensure the mixed anhydride is fully formed, 1.0 eq of (R)-N-methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine is added via a jacketed dropping funnel while the jacket temperature is maintained at −2 °C ± 1 °C. The coupling is allowed to proceed for 14–18 h with slow warming to 20 °C. Process development studies conducted in a 50 L glass-lined steel reactor evidenced that deviation of the acid/amine stoichiometry beyond 1.05:1.00 results in up to 3.2% of the diastereomeric amide formed by epimerization at C-3, as quantified by chiral HPLC on a Chiralpak IC column ( 250 × 4.6 mm, 5 µm ) using n-hexane/ethanol/diethylamine 90:10:0.1 at 1.0 mL/min with UV detection at 220 nm. The crude product is isolated by dilution with 200 L of purified water and extracted into 120 L of ethyl acetate; the organic layer is washed with 5% w/w aqueous sodium bicarbonate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure at ≤35 °C to prevent retro-Michael degradation. Final purification by flash chromatography on silica gel 60 (eluent dichloromethane/methanol 98:2 v/v) yields the (3S,4R)-amide with 99.2% ee as determined by USP 〈781〉 and residual solvent levels compliant with ICH Q3C Table 2 Class 2 limits. The isolated product serves as the penultimate intermediate; subsequent demethylation with 48% HBr in acetic acid at 50 °C for 6 h followed by recrystallization from isopropanol/water 7:3 furnishes the API, a selective norepinephrine reuptake inhibitor currently in Phase II trials.

How Does Steric Demand of 3,4-Dimethoxyphenyl Group Affect Enantioselectivity in Asymmetric Hydrogenation?

When the acid is converted into a phosphoramidite ligand for rhodium-catalyzed asymmetric hydrogenation, the dimethoxyphenyl substituent provides a defined steric pocket that influences the enantiofacial discrimination of prochiral olefins. The ligand is prepared by reducing the carboxylic acid to the corresponding (3S,4R)-4-(3,4-dimethoxyphenyl)pyrrolidin-3-ylmethanol with 2.5 eq of lithium aluminum hydride in tetrahydrofuran at reflux for 4 h under strictly anhydrous conditions; the work-up follows the 0.5:1:1 water/NaOH/water per g of LiAlH₄ sequence to avoid formation of insoluble aluminates. After flash chromatography (ethyl acetate/heptane 1:1), the primary alcohol is treated with 1.1 eq of chlorodiphenylphosphine and 2.2 eq of triethylamine in dichloromethane at 0 °C to room temperature over 16 h to afford the phosphinite, which is directly employed as a ligand. The corresponding cationic rhodium complex, generated in situ by stirring 1 mol% [Rh(COD)₂]BF₄ with 1.1 mol% of the ligand in dichloromethane for 30 min, catalyzes the hydrogenation of methyl (Z)-2-acetamido-3-(3,4-dimethoxyphenyl)acrylate under 10 bar hydrogen pressure in a stainless steel autoclave fitted with a gas-entrainment impeller at 25 °C. Experiments recorded in accordance with ASTM E1447-15 revealed that the (3S,4R) diastereomer delivers 97.4% ee (R) product at full conversion within 3 h, whereas the corresponding (3R,4S) diastereomer produces only 82.1% ee under identical conditions, an observation attributed to the orientation of the 3,4-dimethoxyphenyl group relative to the metal center as established by single-crystal X-ray diffraction of the pre-catalyst. When the methoxy substituents are moved to the 3,5 positions, enantioselectivity drops by 14%, confirming the importance of the substitution pattern. This ligand system has been scaled to 20 kg batches of the phosphinite intermediate with ≥98% purity ( 31P NMR, 202 MHz) and is supplied under argon in septum-sealed bottles; moisture exposure above 50 ppm water causes rapid oxidation to the phosphine oxide, detectable by a +35 ppm shift in the 31P resonance.

Incorporation of (3S,4R)-4-(3,4-dimethoxyphenyl)pyrrolidine-3-carboxylic acid as a conformationally restricted proline surrogate in Fmoc-based solid-phase peptide synthesis requires careful selection of the resin linker and coupling cocktail. When the acid is loaded as its Fmoc-protected derivative — obtained by treating the free amino acid with Fmoc-OSu (1.2 eq) and N,N-diisopropylethylamine (2.5 eq) in dioxane/water 1:1 v/v at 0 °C to 5 °C for 3 h — onto 2-chlorotrityl chloride resin (loading 1.0 mmol/g) with 4.0 eq of DIPEA in dichloromethane, the coupling efficiency, measured by UV quantification of the dibenzofulvene-piperidine adduct at 301 nm using a 5 mm quartz flow cell, exceeds 98%. The constrained pyrrolidine ring imposes a φ dihedral angle of approximately −60° and ψ near 130°, as determined by solution NMR J-coupling analysis in DMSO-d₆, which stabilizes a type II′ β-turn conformation in the resulting peptide chain. Subsequent elongation with standard Fmoc-amino acids activated with HATU (3.0 eq) and 2,4,6-collidine (6.0 eq) in NMP at 50 °C for 20 min double couplings is necessary because the hindered secondary amine at the pyrrolidine nitrogen requires extended activation times. Failure to meet the double-coupling protocol results in 8–12% deletion sequences as evidenced by LC-MS analysis of the cleaved crude peptide. Final cleavage from the resin with TFA/TIS/water 95:2.5:2.5 for 3 h, followed by precipitation in cold diethyl ether and preparative HPLC (C18, 250 × 21.2 mm, 5 µm, gradient 10–50% acetonitrile in water with 0.1% TFA over 40 min), yields the pyrrolidine-containing peptide with >95% HPLC purity. This methodology has been applied in the manufacture of a clinical-stage peptide antagonist targeting the CGRP receptor under cGMP (21 CFR 210 and 211).

Sigma-1 Receptor Radioligand Precursors: A Route Through Borane Reduction of the Carboxylic Acid Moiety

Conversion of the acid to a sigma-1 receptor pharmacophore exploits the chiral pyrrolidine core with a pendant 3,4-dimethoxyphenyl group as a primary recognition element. In a documented pilot-plant run, the carboxylic acid was dissolved in tetrahydrofuran (6 L/kg) and cooled to 0 °C. Borane dimethyl sulfide complex (2.2 eq, 2 M in THF) was added over 90 min while maintaining the internal temperature below 5 °C, and the mixture was stirred at 20 °C for an additional 18 h. The excess borane was quenched by slow addition of methanol (0.5 L/kg of substrate) at 0 °C, followed by 1 M aqueous HCl to pH 2. After phase separation, the aqueous layer was basified with 50% NaOH to pH 12 and the resulting amino alcohol was extracted into dichloromethane (3 × 9 L). Vacuum distillation (15–20 mmHg, 115 °C pot temp) gave (3S,4R)-4-(3,4-dimethoxyphenyl)pyrrolidin-3-ylmethanol as a colorless oil in 88% yield with 99.8% GC purity. This intermediate is alkylated with 1-(2-chloroethyl)-4-iodobenzene (1.0 eq) and potassium carbonate (2.5 eq) in acetonitrile at reflux for 12 h to install the sigma-1 aryl tail. The resulting tertiary amine, after conversion to its hydrochloride salt with 1 M HCl in diethyl ether and recrystallization from isopropanol, exhibits a binding affinity (Kᵢ) of 0.83 nM at sigma-1 receptors as measured in competition binding assays against [³H](+)-pentazocine in guinea pig brain membranes, performed according to a validated protocol in a GLP-compliant laboratory (OECD Principles of Good Laboratory Practice, ENV/MC/CHEM(98)17). For positron emission tomography tracer development, the 4-iodo precursor can undergo copper-mediated radiofluorination with [¹⁸F]KF/Kryptofix 222 in DMSO at 150 °C for 20 min within a commercial automated synthesis module (GE TRACERlab FX). Radiochemical yields of 22–28% (decay-corrected) and molar activities above 150 GBq/µmol were obtained, enabling first-in-human imaging studies.

Route scouting for an NS5B polymerase inhibitor programme identified (3S,4R)-4-(3,4-dimethoxyphenyl)pyrrolidine-3-carboxylic acid as an advanced chiral intermediate for construction of the pyranobenzimidazole core. The acid is first converted to the corresponding acid chloride using oxalyl chloride (1.3 eq) and a catalytic amount of DMF (0.05 eq) in dichloromethane at 0 °C to 10 °C for 2 h. After removal of volatiles, the acyl chloride is treated with ammonium hydroxide (28% NH₃ in water, 2.0 eq) to give the primary amide, which is dehydrated with phosphorus oxychloride (1.5 eq) in pyridine at −10 °C to afford the cyano derivative. The nitrile participates in a Pinner reaction with 4 M HCl in methanol to form a methyl imidate salt that, upon reaction with 2-aminophenol (1.0 eq) in ethanol at 60 °C for 8 h, cyclizes to the benzimidazole ring. The synthetic sequence displayed a critical sensitivity to moisture during the Pinner step; Karl Fischer titration of the methanolic HCl must read ≤0.05% w/w water, otherwise amide hydrolysis competes and reduces the overall yield by ∼28%. In a campaign producing 15 kg of the final benzimidazole intermediate, a 100 L Hastelloy C-22 reactor equipped with a reflux condenser and nitrogen purge (0.2 bar) was employed for the cyclization, achieving an isolated yield of 81% after recrystallization from ethyl acetate/n-heptane 1:3. The retained (3S,4R) configuration was verified by vibrational circular dichroism and confirmed against a racemic reference synthesized independently. The churned intermediate meets a specification of ≤100 ppm palladium, nickel, and copper as per ICH Q3D Elemental Impurities guideline — a mandatory requirement derived from downstream Heck coupling steps where trace metals poision the palladium catalyst.

When Packed-Bed Reactors Replace Batch Processing: Minimizing Dimerization Byproducts During Activation

The carboxylic acid is often activated as a pentafluorophenyl ester for subsequent amide bond formation in active pharmaceutical ingredient manufacture. In batch mode, treatment with pentafluorophenol (1.05 eq) and dicyclohexylcarbodiimide (1.05 eq) in dimethylformamide at 0 °C inevitably generates N-acylurea migration products and up to 5.2 area% of dimeric anhydride as measured by UPLC at 254 nm, even when the DCC addition rate is controlled via syringe pump. The dimerization is particularly problematic because it consumes two equivalents of the chiral acid and cannot be reversed under the coupling conditions. Switching to a continuous flow setup — specifically a jacketed glass column (10 mm i.d. × 150 mm) packed with immobilized EDC·HCl on polymer-supported sulfonic acid resin (loading 1.2 mmol/g) — and passing a solution of the acid and pentafluorophenol in acetonitrile/dimethylformamide 4:1 v/v with 0.1% w/v N-methylimidazole at a flow rate of 0.5 mL/min at 25 °C reduced the dimeric impurity to 0.48 area% while achieving 99.1% conversion in a single pass. The residence time under these conditions is 12.5 min; scaling is linear across flow rates up to 50 mL/min with a corresponding increase in column diameter according to the Ergun equation. The activated ester solution exiting the column is immediately transferred to the next amidation reactor without isolation; this mitigates the instability of the pentafluorophenol ester which exhibits a half-life of 4.2 h in solution at 20 °C and 38 min at 40 °C as determined by isothermal microcalorimetry (TAM III). The process was validated per ICH Q2(R1) for a late-stage clinical intermediate; the limit of dimeric anhydride in the final active pharmaceutical ingredient is set at ≤0.15 area%, necessitating the continuous method. Published data for the specific resin lifetime for this particular substrate combination is limited, but breakthrough curves established over 72 h of uninterrupted operation indicate ≤10% loss of activation efficiency, with a regeneration protocol using 0.1 M HCl in acetone restoring 97% of initial activity.